News | Prostate Cancer | November 19, 2018

Higher Pretreatment Immune Inflammatory Levels Linked to Lower Disease-Free Survival in Prostate Cancer

Validation study from NRG-RTOG 0521 also suggests no association between elevated C-reactive protein and disease-free survival

Immune Inflammatory Levels Linked to Disease-Free Survival in Prostate Cancer

November 19, 2018 — Data from a validation study of a high-risk prostate cancer trial suggests that higher levels of pretreatment interleukin 10 (IL-10) were linked to lower rates of disease-free survival (DFS). The data suggests there is no association between an elevated level of C-reactive protein (CRP) and DFS. Results were presented at the 60th Annual Meeting of the American Society for Radiation Oncology (ASTRO), Oct. 21-24 in San Antonio, Texas.

The initial study, NRG-RTOG 0521, indicated that elevated CRP levels, a marker of inflammation, were directly associated with shorter biochemical failure-free survival after radiotherapy for patients with high-risk prostate cancer. During this study, serum samples were collected from 202 participants and banked for future biomarker validation. Researchers measured multiple serum immuno-inflammatory cytokines in addition to CRP levels. The primary objective for the validation study was to determine the association between CRP levels and DFS from time of patient randomization, and additional objectives included the correlation of cytokine levels with DFS and toxicity events due to radiotherapy.

“Although CRP levels did not correlate with DFS, the association of higher baseline levels of IL-10 with poorer outcome supports the claim that there may be an interaction between host pretreatment immune inflammatory state and the outcomes for the patient following radiotherapy treatment. I believe that future investigation into anti-inflammatory medical intervention for patients with prostate cancer in association to radiotherapy would be worthwhile,” stated William A. Hall, M.D., an assistant professor of radiation oncology at the Medical College of Wisconsin and lead author of this abstract.

Serum immune-inflammatory cytokines that were studied included:

  • Monocyte chemotactic protein-1 (MCP-1);
  • Granulocyte-macrophage colony-stimulating factor (GM-CSF);
  • Interferon gamma (IFN-γ);
  • IL-1b;
  • IL-2;
  • IL-4;
  • IL5;
  • IL-6;
  • IL-8;
  • IL-10;
  • IL-12;
  • IL-13;
  • IL-17A;
  • IL-23; and
  • Tumor necrosis factor (TNFα).

In addition to the association between IL-10 and DFS, IL-12 and IL-13 were also associated with grade 2 or higher cystitis, or inflammation of the bladder.

For more information: www.astro.org

Related Content

Radiotherapy has been used to treat cancers for more than a century and continues to be utilized in cancer treatment plans today. Since the introduction of radiotherapy, clinicians have been working tirelessly to further refine treatments to better target cancer.
Feature | Radiation Therapy | July 06, 2020 | By Yves Archambault
Everything has room for improvement, right? Right. When it comes to cancer care, it is no different.
Proton therapy has evolved, and future predictions include smaller systems, more sophisticated proton dosimetry and devices that manipulate the proton beam
Feature | Proton Therapy | July 06, 2020 | By Minesh Mehta, M.D.
The field of proton...
Researchers reviewed results of prostate biopsies on over 3,400 men who had targets identified on prostate MRI and found that the positive predictive value of the test for prostate cancer was highly variable at different sites
News | Prostate Cancer | July 01, 2020
July 1, 2020 — Prostate MRI is an emerging technology used to identify and guide treatment for...
R2* maps of healthy control participants and participants with Alzheimer disease. R2* maps are windowed between 10 and 50 sec21. Differences in iron concentration in basal ganglia are too small to allow visual separation between patients with Alzheimer disease and control participants, and iron levels strongly depend on anatomic structure and subject age. Image courtesy of Radiological Society of North America

R2* maps of healthy control participants and participants with Alzheimer disease. R2* maps are windowed between 10 and 50 sec21. Differences in iron concentration in basal ganglia are too small to allow visual separation between patients with Alzheimer disease and control participants, and iron levels strongly depend on anatomic structure and subject age. Image courtesy of Radiological Society of North America

News | Magnetic Resonance Imaging (MRI) | July 01, 2020
July 1, 2020 — Researchers using magnetic...
Thoracic findings in a 15-year-old girl with Multisystem Inflammatory Syndrome in Children (MIS-C). (a) Chest radiograph on admission shows mild perihilar bronchial wall cuffing. (b) Chest radiograph on the third day of admission demonstrates extensive airspace opacification with a mid and lower zone predominance. (c, d) Contrast-enhanced axial CT chest of the thorax at day 3 shows areas of ground-glass opacification (GGO) and dense airspace consolidation with air bronchograms. (c) This conformed to a mosai

Thoracic findings in a 15-year-old girl with Multisystem Inflammatory Syndrome in Children (MIS-C). (a) Chest radiograph on admission shows mild perihilar bronchial wall cuffing. (b) Chest radiograph on the third day of admission demonstrates extensive airspace opacification with a mid and lower zone predominance. (c, d) Contrast-enhanced axial CT chest of the thorax at day 3 shows areas of ground-glass opacification (GGO) and dense airspace consolidation with air bronchograms. (c) This conformed to a mosaic pattern with a bronchocentric distribution to the GGO (white arrow, d) involving both central and peripheral lung parenchyma with pleural effusions (black small arrow, d). image courtesy of Radiological Society of North America

News | Coronavirus (COVID-19) | June 26, 2020
June 26, 2020 — In recent weeks, a multisystem hyperinflammatory condition has emerged in children in association wit
Case abstraction study period was from 10 March to 7 April 2020. Follow-up of abstracted cases was until 7 May 2020.

Case abstraction study period was from 10 March to 7 April 2020. Follow-up of abstracted cases was until 7 May 2020. Courtesy of Nature Medicine

News | Coronavirus (COVID-19) | June 25, 2020
June 25, 2020 — The characterization of COVID-19
Neurosurgeon Jason Sheehan, M.D., Ph.D., of UVA Health, is pioneering the use of focused ultrasound to treat glioblastoma, the deadliest brain tumor. Image courtesy of UVA Health

Neurosurgeon Jason Sheehan, M.D., Ph.D., of UVA Health, is pioneering the use of focused ultrasound to treat glioblastoma, the deadliest brain tumor. Image courtesy of UVA Health

News | Focused Ultrasound Therapy | June 23, 2020
June 23, 2020 — An innovativ...